tradingkey.logo
tradingkey.logo
Suchen

Transmedics Group Inc

TMDX
Zur Watchlist hinzufügen
67.850USD
+1.430+2.15%
Handelsschluss 07/01, 16:00ETKurse um 15 Minuten verzögert
2.34BMarktkapitalisierung
13.44KGV TTM

mehr Informationen über Transmedics Group Inc Unternehmen

TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

Transmedics Group Inc Informationen

BörsenkürzelTMDX
Name des UnternehmensTransmedics Group Inc
IPO-datumMay 02, 2019
CEOHassanein (Waleed H)
Anzahl der mitarbeiter728
WertpapierartOrdinary Share
GeschäftsjahresendeMay 02
Addresse200 Minuteman Road
StadtANDOVER
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl01810
Telefon19785520900
Websitehttps://www.transmedics.com/
BörsenkürzelTMDX
IPO-datumMay 02, 2019
CEOHassanein (Waleed H)

Führungskräfte von Transmedics Group Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
564.33K
+14.66%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
188.13K
+1.55%
Mr. Thomas James Gunderson
Mr. Thomas James Gunderson
Independent Director
Independent Director
16.64K
+58.05%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
15.11K
+19.34%
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
14.35K
+57.82%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
6.98K
+41.86%
Ms. Stephanie Lovell
Ms. Stephanie Lovell
Independent Director
Independent Director
5.79K
+50.48%
Mr. Gerardo Hernandez
Mr. Gerardo Hernandez
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
3.00K
+88.95%
Dr. Tamer I. Khayal, M.D.
Dr. Tamer I. Khayal, M.D.
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Edward M. Basile
Mr. Edward M. Basile
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
564.33K
+14.66%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
188.13K
+1.55%
Mr. Thomas James Gunderson
Mr. Thomas James Gunderson
Independent Director
Independent Director
16.64K
+58.05%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
15.11K
+19.34%
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
14.35K
+57.82%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
6.98K
+41.86%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Transmedics Group Inc?

Die fünf größten Anteilseigner von Transmedics Group Inc sind: Dr. Waleed H. Hassanein, M.D.

Wie viele Institutionen halten Anteile an Transmedics Group Inc (TMDX)?

Mit Stand vom 2026Q1 halten 865 Institutionen Anteile an Transmedics Group Inc, mit einem Gesamtmarktwert von etwa 42.29M, was 122.36% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1737478.00 gestiegen.

Was ist die größte Einnahmequelle von Transmedics Group Inc?

Am 2026Q1 erzielte das Geschäft mit OCS Liver net revenue für Transmedics Group Inc den höchsten Umsatz in Höhe von 460.53M, was 76.58% des Gesamtumsatzes entspricht.